- Home
- LICN vs ATHA Comparison
LICN vs ATHA Comparison
Compare LICN & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- ATHA
- Stock Information
- Founded
- LICN 2004
- ATHA 2011
- Country
- LICN China
- ATHA United States
- Employees
- LICN N/A
- ATHA N/A
- Industry
- LICN
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- LICN
- ATHA Health Care
- Exchange
- LICN Nasdaq
- ATHA Nasdaq
- Market Cap
- LICN 83.8M
- ATHA 93.5M
- IPO Year
- LICN 2023
- ATHA 2020
- Fundamental
- Price
- LICN $1.82
- ATHA $0.72
- Analyst Decision
- LICN
- ATHA Buy
- Analyst Count
- LICN 0
- ATHA 4
- Target Price
- LICN N/A
- ATHA $11.25
- AVG Volume (30 Days)
- LICN 612.3K
- ATHA 14.2M
- Earning Date
- LICN 11-26-2024
- ATHA 11-07-2024
- Dividend Yield
- LICN N/A
- ATHA N/A
- EPS Growth
- LICN 36.90
- ATHA N/A
- EPS
- LICN 0.28
- ATHA N/A
- Revenue
- LICN $41,929,000.00
- ATHA N/A
- Revenue This Year
- LICN N/A
- ATHA N/A
- Revenue Next Year
- LICN N/A
- ATHA N/A
- P/E Ratio
- LICN $6.57
- ATHA N/A
- Revenue Growth
- LICN 24.86
- ATHA N/A
- 52 Week Low
- LICN $0.50
- ATHA $0.41
- 52 Week High
- LICN $2.44
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- LICN 43.65
- ATHA 57.38
- Support Level
- LICN $1.96
- ATHA $0.60
- Resistance Level
- LICN $2.31
- ATHA $0.83
- Average True Range (ATR)
- LICN 0.20
- ATHA 0.10
- MACD
- LICN -0.00
- ATHA 0.04
- Stochastic Oscillator
- LICN 16.67
- ATHA 80.59
About LICN Lichen China Limited
Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.